摘要
目的测定老年血液系统恶性肿瘤合并贫血患者红细胞生成素(EPO)、可溶性转铁蛋白受体(sTfR)的水平并对其临床意义进行研究。方法选取贫血患者142例,根据疾病类型不同将患者分为血液肿瘤贫血组(n=41)、实体肿瘤贫血组(n=51)、缺铁性贫血组(n=50)。比较3组患者的血清EPO、sTfR水平,并对EPO、sTfR与血红蛋白(Hb)的相关性进行分析。结果 3组患者的Hb水平比较,差异无统计学意义(P﹥0.05);血液肿瘤贫血组和缺铁性贫血组患者的EPO水平比较,差异无统计学意义(P﹥0.05);血液肿瘤贫血组和缺铁性贫血组患者的EPO水平均高于实体肿瘤贫血组(P﹤0.05);血液肿瘤贫血组和实体肿瘤贫血组患者的sTfR水平均低于缺铁性贫血组(P﹤0.05);缺铁性贫血组患者的Hb与EPO、sTfR均呈负相关(r=-0.861、-0.546,P﹤0.01)。结论血液肿瘤患者的贫血机制可能并非源于EPO生成不足,而是由于骨髓红系造血功能受到抑制。
Objective To determine the level of erythropoietin（EPO） and soluble transferrin receptor（sTfR） in elderly patients with anemia combined with hematologic malignancies and to evaluate the clinical significance. Method 142 patients with anemia were included in the study, by different clinical diagnosis, the patients were stratified as hematologic malignancies combined with anemia group（n=41）, solid tumors combined with anemia group（n=51） and iron deficiency anemia group（n=50）. The levels of serum EPO and sTfR in the three groups were compared, and the correlation among EPO, sTfR and hemoglobin（Hb） were analyzed. Result There was no significant difference in Hb levels among the three groups（P〉0.05）. No significant difference was observed in EPO levels between hematologic malignancies plus anemia group and iron deficiency anemia group（P〉0.05）; the EPO level in patients with hematologic malignancies plus anemia or with iron deficiency anemia was higher than that in those with solid tumors combined with anemia（P〈0.05）; the sTfR levels in patients with hematologic malignancies combined with anemia and solid tumors in combination with anemia were lower than in those with iron deficiency anemia（P〈0.05）; there was a negative correlation between Hb, and EPO or sTfR in patients with iron deficiency anemia（r=-0.861,-0.546, P〈0.01）. Conclusion The mechanism of anemia in patients with hematologic malignancies may not be the lack of EPO production, but is likely due to the inhibition of erythroid hematopoiesis in the bone marrow.
作者
李莉
张文龙
张骥
卜思践
LI Li;ZHANG Wenlong;ZHANG Ji;BU Sijian(Department of Hematology,Shanghai Putuo District People＇s Hospital,Shanghai 200060,Chin)
出处
《癌症进展》
2018年第7期908-910,927,共4页
Oncology Progress
